[1] TANG A, HALLOUCH O, CHERNYAK V, et al.Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis[J]. Abdom Radiol (NY), 2018, 43(1): 13-25. [2] THRIFT A P, NATARAJAN Y, LIU Y, et al. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality[J]. Clin Gastroenterol Hepatol, 2019, 17(10): 2117-2125.e.3. [3] RICH N E, YOPP A C, SINGAL A G.Medical Management of Hepatocellular Carcinoma[J]. J Oncol Pract, 2017, 13(6): 356-364. [4] CHEN L T, MARTINELLI E, CHENG A L, et al.Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO[J]. Ann Oncol, 2020, 31(3): 334-351. [5] COURI T, PILLAI A.Goals and targets for personalized therapy for HCC[J]. Hepatol Int, 2019, 13(2): 125-137. [6] MORSE M A, SUN W, KIM R, et al.The Role of Angiogenesis in Hepatocellular Carcinoma[J]. Clin Cancer Res, 2019, 25(3): 912-920. [7] ZHU D, HUNTER S B, VERTINO P M, et al.Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1[J]. Cancer Res, 2011, 71(17): 5859-5870. [8] XU L, DU H, ZHANG Q, et al.BAI1-associated protein 2-like 2 is a potential biomarker in lung cancer[J]. Oncol Rep, 2019, 41(2): 1304-1312. [9] HAMANN J, AUST G, ARAC D, et al.International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors[J]. Pharmacol Rev, 2015, 67(2): 338-367. [10] HATANAKA H, OSHIKA Y, ABE Y, et al.Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1)[J]. Int J Mol Med, 2000, 5(2): 181-183. [11] CORK S M, VAN MEIR E G. Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development[J]. J Mol Med (Berl), 2011, 89(8): 743-752. [12] YI M, JIAO D, QIN S, et al.Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J]. Mol Cancer, 2019, 18(1): 60. [13] REN F, WU K, YANG Y, et al.Dandelion Polysaccharide Exerts Anti-Angiogenesis Effect on Hepatocellular Carcinoma by Regulating VEGF/HIF-1alpha Expression[J]. Front Pharmacol, 2020, 11: 460. [14] LIU L, CHAI L, RAN J, et al.BAI1 acts as a tumor suppressor in lung cancer A549 cells by inducing metabolic reprogramming via the SCD1/HMGCR module[J]. Carcinogenesis, 2020, 41(12): 1724-1734. [15] HOLST F, HOIVIK E A, GIBSON W J, et al.Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth[J]. Sci Rep, 2016, 6: 25521. [16] ZHANG H, ZHU D, ZHANG Z, et al.EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway[J]. Oncogene, 2020, 39(5): 1041-1048. [17] KAUR B, BRAT D J, DEVI N S, et al.Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor[J]. Oncogene, 2005, 24(22): 3632-3642. [18] NAM D H, PARK K, SUH Y L, et al.Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance[J]. Oncol Rep, 2004, 11(4): 863-869. [19] CORK S M, KAUR B, DEVI N S, et al.A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1[J]. Oncogene, 2012, 31(50): 5144-5152. [20] TIAN D W, HU H L, SUN Y, et al.Biological effects of eukaryotic recombinant plasmid pReceiver-M61-BAI-1 transfection on T24 cells and HUVECs[J]. Mol Med Rep, 2016, 14(2): 1553-1559. [21] WEN Y, ZHOU X, LU M, et al.Bclaf1 promotes angiogenesis by regulating HIF-1alpha transcription in hepatocellular carcinoma[J]. Oncogene, 2019, 38(11): 1845-1859. [22] HORWITZ E, STEIN I, ANDREOZZI M, et al.Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment[J]. Cancer Discov, 2014, 4(6): 730-743. [23] LEI T, LING X.IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation[J]. World J Gastroenterol, 2015, 21(35): 10137-10149. [24] LUGANO R, RAMACHANDRAN M, DIMBERG A.Tumor angiogenesis: causes, consequences, challenges and opportunities[J]. Cell Mol Life Sci, 2020, 77(9): 1745-1770. [25] LI H.Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(3): 217-233. [26] HUANG A, YANG X R, CHUNG W Y, et al.Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1): 146. [27] RIBATTI D, VACCA A, NICO B, et al.Angiogenesis and anti-angiogenesis in hepatocellular carcinoma[J]. Cancer Treat Rev, 2006, 32(6): 437-444. |